article Open AccessTop 1% cited
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
Oncotarget · 2015 · Vol. 6(27) · pp. 24560–24570
Talia Golan✉(Tel Aviv University)Elina Zorde KhvalevskyAyala Hubert(Hadassah Medical Center)Rachel Malka GabaiNaama HenAmiel Segal(Shaare Zedek Medical Center)Abraham J. Domb(Hebrew University of Jerusalem)Gil HarariEliel Ben-David(Hebrew University of Jerusalem)Stephen Raskin(Tel Aviv University)Yuri Goldes(Tel Aviv University)Eran Goldin(Shaare Zedek Medical Center)Rami Eliakim(Tel Aviv University)Maor Lahav(Tel Aviv University)Yael Kopleman(Hadassah Medical Center)Alain Dancour(Shaare Zedek Medical Center)Amotz ShemiEithan Galun(Hadassah Medical Center)
Abstract
The combination of siG12D-LODER™ and chemotherapy is well tolerated, safe and demonstrated a potential efficacy in patients with LAPC. NCT01188785.
Pancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer StudiesCancer Research and TreatmentsMedicineGemcitabineFOLFIRINOXPancreatic cancerInternal medicineAdverse effectKRASOncologyChemotherapyCancer
MeSH terms
RNAi TherapeuticsIrinotecanOxaliplatinGemcitabineAgedAged, 80 and overAntigens, NeoplasmAntineoplastic AgentsCamptothecinLeucovorinCombined Modality TherapyDeoxycytidineDrug ImplantsFemaleFluorouracil
Citations
318
FWCI
11.21
field-weighted impact
References
21
Percentile
99%
vs. same field & year
Citations per year
Cited by
Noncoding RNA therapeutics — challenges and potential solutions
Nature Reviews Drug Discovery · 2021 · 1,517 citations
References
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
New England Journal of Medicine · 2011 · 7,636 citations
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
New England Journal of Medicine · 2013 · 6,561 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.